Daix (France), Long Island City (New York, United States), March 22, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of steatohepatitis associated with metabolic dysfunction
(MASH), or NASH, and other diseases with an unmet medical need, today announces that its management team will present the Company’s 2023 financial results on Thursday, March 28, 2024, during a webcast presentation .